European journal of breast health最新文献

{"title":"Role of Radiotherapy in Elderly Patients (≥65 Years) With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.","authors":"Eran Sharon, Igor Snast, Rinat Yerushalmi, Idit Melnik","doi":"10.4274/ejbh.galenos.2025.2025-2-10","DOIUrl":"10.4274/ejbh.galenos.2025.2025-2-10","url":null,"abstract":"<p><p>This is the first meta-analysis evaluating the benefit of adjuvant radiotherapy in older patients (≥65 years) with triple-negative breast cancer (TNBC). The medical literature was searched for all randomized controlled trials, nonrandomized controlled trials, and cohort studies with more than one treatment arm that evaluated radiation therapy for TNBC in patients aged >65 years. The primary outcome was overall survival. Four cohort studies (2015-2019) were eligible for analysis, including a total of 10,710 patients with TNBC of whom 7,209 underwent radiotherapy. Two were large retrospective population-based studies that yielded major findings on adjusted multivariable analysis. Patients who underwent radiotherapy (<i>n</i> = 6283/8526) had a significantly better 5-year overall survival than patients who did not (77% <i>vs.</i> 55%, <i>p</i><0.001). The addition of radiotherapy (<i>n</i> = 815/1957) was associated with better cancer-specific survival. Of the two smaller studies, one prospective study reported similar survivability for treatment with breast-conserving surgery, chemotherapy, and radiotherapy or mastectomy with radiation, or mastectomy alone, and the other retrospective study found that adding radiotherapy had no effect on 5-year overall survival. Multivariate analyses of data from the two large retrospective population-based studies suggested that adding radiotherapy to breast-conserving surgery may improve overall and disease-free survival in elderly patients with TNBC.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"285-289"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>ROPN1</i> Gene Expression as a Prognostic and Predictive Biomarker in Aggressive Breast Cancer: Clinical Implications and Survival Association.","authors":"Ricardo Cesar Cintra, Andrés Galindo Céspedes, Olinda Maria Gamarra, Carlos Javier Melgarejo, Daniel Rodrigues de Bastos","doi":"10.4274/ejbh.galenos.2025.2025-6-2","DOIUrl":"10.4274/ejbh.galenos.2025.2025-6-2","url":null,"abstract":"<p><strong>Objective: </strong>The <i>ropporin-1</i> (<i>ROPN1</i>) gene, initially linked to sperm motility, is differentially expressed in triple negative breast cancer (TNBC), suggesting a role in tumor progression and therapy resistance. To characterize <i>ROPN1</i> expression in breast cancer and evaluate its association with clinicopathological features, survival, and treatment response as a translational biomarker.</p><p><strong>Materials and methods: </strong>Data from The Cancer Genome Atlas (1,087 patients), Sweden Cancerome Analysis Network-Breast (3,273 patients), and geodatabases were analyzed. <i>ROPN1</i> transcriptional levels were assessed in relation to clinical variables and survival. Chemotherapy agents and epigenetic modulators were tested in cell lines to evaluate <i>ROPN1</i> regulation.</p><p><strong>Results: </strong>Transcriptional overexpression of <i>ROPN1</i> was significantly enriched in TNBC/basal-like tumors (<i>p</i><0.0001) and correlated with reduced overall survival, particularly in basal cases [hazard ratio (HR) = 1.85; 95% confidence interval (CI): 1.02-3.33; <i>p</i> = 0.041]. Patients treated with chemotherapy and exhibiting high <i>ROPN1</i> levels had unfavorable prognosis, with an even poorer profile in untreated cohorts (HR = 4.55; 95% CI: 1.33-14.29; <i>p</i> = 0.01). Hypomethylation at cg00101712 (HR = 0.59; <i>p</i> = 0.016) and cg09298623 (HR = 0.49; <i>p</i> = 0.0014) CpG sites were associated with worse survival at 5 years follow-up, underscoring epigenetic regulation of this pathway as a key driver of poor outcomes. Furthermore, <i>in vitro</i> treatment with cisplatin, doxorubicin, and paclitaxel resulted in variable responses, with a significant reduction of <i>ROPN1</i> in HCC70 and HS578T cell lines, while BT549 and MDA-MB-231 cell lines showed notable increases.</p><p><strong>Conclusion: </strong><i>ROPN1</i> overexpression in TNBC/basal-like tumors suggests a role as a prognostic biomarker and predictor of post-chemotherapy resistance. Investigation of <i>ROPN1</i> expression in breast tumors may lead to alternative strategies targeting pro-metastatic pathways and improve precision treatment for aggressive breast cancer.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"345-355"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoangiomatous Hyperplasia of Mammary Stroma: Insights from Two Cases, Data Update and Management Algorithm.","authors":"Caroline Bouche, Thibaut Wolf, Mégane Buttignol, Carole Mathelin","doi":"10.4274/ejbh.galenos.2025.2025-3-8","DOIUrl":"10.4274/ejbh.galenos.2025.2025-3-8","url":null,"abstract":"<p><p>Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast lesion frequently discovered incidentally during imaging or biopsy for other conditions. We present two cases of PASH associated with fibroadenomas in premenopausal women, both presenting as palpable, symptomatic breast masses. In the first case, a 26-year-old woman exhibited a 5.2 cm hypoechoic lesion, initially diagnosed as PASH on core biopsy, later confirmed as fibroadenoma with PASH components post-excision. The second case involved a 37-year-old woman with a painful 5.6 cm mass, diagnosed similarly via biopsy, and later confirmed as fibroadenoma fully colonized by PASH after surgical removal. Both cases highlight the diagnostic challenge in distinguishing PASH from fibroadenomas, given overlapping clinical and imaging features. Hormonal factors, particularly contraceptive use, may contribute to PASH development. Management remains controversial, with surgery indicated for symptomatic lesions, while conservative approaches may suffice for smaller, asymptomatic cases. Based on our findings and current literature, we propose a management algorithm to guide clinicians in differentiating cases warranting surgical intervention from those suitable for monitoring. Further studies are needed to validate this approach.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"375-378"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.","authors":"Senem Alanyalı, Emre Karaman, Murat Köylü, Ümit Kahraman, Sanem Nalbantgil","doi":"10.4274/ejbh.galenos.2025.2025-3-5","DOIUrl":"10.4274/ejbh.galenos.2025.2025-3-5","url":null,"abstract":"<p><p>The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"379-383"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Serum STARD3 Levels in Patients With Breast and Prostate Cancer: A Case-Control Study.","authors":"Almila Nazlı Korucu, Mine Büşra Bozkurk, Dilara Şevval Anasız, Ahmet Nihat Karakoyunlu, Şener Balas, Alpaslan Öztürk, Nihal İnandıklıoğlu","doi":"10.4274/ejbh.galenos.2025.2025-5-1","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-1","url":null,"abstract":"<p><strong>Objective: </strong>Cancer cells exhibit high metabolic demands and rely heavily on lipid metabolism for proliferation and membrane synthesis. Lipid transfer proteins, particularly the steroidogenic acute regulatory-related lipid transfer domain 3 (STARD3), play a significant role in intracellular cholesterol transport and may influence cancer progression. The aim of this study was to investigate serum STARD3 levels in patients with breast and prostate cancer and compare them with healthy controls, along with lipid parameters.</p><p><strong>Materials and methods: </strong>Patients with breast cancer (women) and prostate cancer (men) were recruited together with a control group matched by age-range and sex. Serum samples were collected, and STARD3 levels were measured using a commercial ELISA kit. Lipid parameters and tumor markers (carbohydrate antigen 15-3, prostate-specific antigen) were also evaluated.</p><p><strong>Results: </strong>A total of 200 individuals were enrolled: 50 female breast cancer patients, 50 male prostate cancer patients, and 100 healthy controls. STARD3 levels were significantly lower in both breast cancer (<i>p</i> = 0.045) and prostate cancer (<i>p</i><0.001) groups compared to controls. However, no significant correlation was found between STARD3 levels and other biochemical parameters or tumor stage in either cancer group.</p><p><strong>Conclusion: </strong>The results suggest that STARD3 may play a role in the pathogenesis of both hormone-related cancers, although the mechanism remains unclear. Given the limited studies evaluating STARD3 in both breast and prostate cancers simultaneously, our findings contribute novel data to the literature and may guide future research into the diagnostic or prognostic potential of STARD3 in oncology.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"339-344"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Air-Assisted Mastectomy Using LigaSure for a Breast Cancer Patient With a Cardiac Pacemaker.","authors":"Mustafa Tukenmez, Baran Mollavelioglu, Selman Emiroglu, Neslihan Cabioglu, Mahmut Muslumanoglu, Vahit Ozmen","doi":"10.4274/ejbh.galenos.2025.2024-12-4","DOIUrl":"10.4274/ejbh.galenos.2025.2024-12-4","url":null,"abstract":"<p><p>Mastectomy is often performed using unipolar electrocautery. However, for patients with a pacemaker, alternative methods are necessary, as the use of unipolar cautery is not recommended. In the case presented herein, we made half-centimeter incisions on the skin to be removed. We then pumped air under the mastectomy flaps through these incisions using a hand pump and a lipoplasty cannula equipped with a filter. Following this, we made a Stewart incision and conducted the dissection using a LigaSure vessel-sealing device from the plane formed by the air. The surgery was successfully completed without any significant bleeding, and the patient was discharged without any complications. Notably, this innovative surgical technique was employed for the first time in a breast cancer patient. The cannula we developed has facilitated the creation of a dissection plane using air, similar to endoscopic mastectomy, without requiring additional ports or equipment. This technique has the potential to facilitate surgery for selected patients.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"384-386"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes.","authors":"Emanuelle Narciso Alvarez Valente, Anke Bergman, Marcelo Adeodato Bello, Luiz Claudio Santos Thuler","doi":"10.4274/ejbh.galenos.2025.2025-5-6","DOIUrl":"10.4274/ejbh.galenos.2025.2025-5-6","url":null,"abstract":"<p><strong>Objective: </strong>The use of neoadjuvant chemotherapy (NAC) has improved outcomes in breast cancer (BC). The residual cancer burden index (RCB) predicts prognosis. This study evaluated RCB as a prognosticator in BC subtypes treated with NAC.</p><p><strong>Materials and methods: </strong>A retrospective cohort of BC patients was analyzed. Five-year distant recurrence-free survival (DRFS), disease-free survival (DFS), and overall survival (OS) were analyzed. Statistical analyses included descriptive statistics, ANOVA, chi-square test, Fisher's exact test, Kaplan-Meier curves, Log-Rank test, and Cox regression.</p><p><strong>Results: </strong>Among 562 women, RCB correlated with BC subtypes and predicted worse DRFS, DFS, and OS. In stratified analyses by molecular subtype, the association was significant only for luminal B and triple-negative subtypes, with inconsistent findings for luminal A and human epidermal growth factor type 2-overexpressed subtypes.</p><p><strong>Conclusion: </strong>The RCB index was shown to be a prognostic marker in BC in a Brazilian population with BC. Significant associations were found only for the luminal B and triple negative subtypes. Further research is required to investigate the prognostic utility of RCB in other larger populations.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"307-325"},"PeriodicalIF":1.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mammographic Breast Pseudocalcifications Associated With Topical Betamethasone Dipropionate.","authors":"Hayes Pearce, Jamie Spoont, Priscila Sanchez Aguirre, Cedric Pluguez-Turull","doi":"10.4274/ejbh.galenos.2025.2025-6-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2025.2025-6-1","url":null,"abstract":"<p><p>Screening mammography plays a critical role in the early detection of breast cancer. Suspicious breast calcifications on mammography often prompt further diagnostic evaluation due to concern for malignancy, worrying physicians and patients alike. Here, we present a case of a woman in her 70s whose annual screening mammogram with digital breast tomosynthesis demonstrated two new groups of microcalcifications, confirmed after recall with magnification views. However, because of their superficial location, biopsy was thought to be too technically challenging and short follow-up was recommended. At 6-month mammographic follow-up, there was interval non-visualization of both calcifications. Additional clinical history interrogation revealed that due to a diffuse pruritic rash, the patient had been applying topical betamethasone dipropionate daily to her entire body, including her breasts, when she received her initial mammogram. This case illustrates how corticosteroid ointments and lotions may mimic suspicious calcifications on mammography, reinforcing the importance of guidelines recommending avoidance of topical products on the day of imaging.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers\".","authors":"Renu Sah","doi":"10.4274/ejbh.galenos.2025.2025-6-7","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2025.2025-6-7","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Ileocecal Metastasis from Lobular Carcinoma of the Breast: A Case Report.","authors":"Lakshmi Radhakrishnan, Ramita Mukherjee, Brijesh Kumar Singh, Yashika Maheswari, Yamini Dharmashaktu, Asuri Krishna, Vuthaluru Seenu","doi":"10.4274/ejbh.galenos.2025.2025-2-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2025.2025-2-5","url":null,"abstract":"<p><p>Invasive lobular carcinoma (ILC) is the second most common histologic subtype of invasive breast cancer, accounting for 5-15% of this type. Though its unique propensity to metastasize to the extra-hepatic gastrointestinal tract is well known, isolated colonic metastasis without disseminated or locoregional recurrence is rare. These isolated lesions may be amenable to curative treatment with a better prognosis. Here we present the diagnostic challenge faced while managing the case of a 62-year-old female who was treated for estrogen receptor-positive ILC of the breast 10-years previously, who presented with an ileocecal mass, which on biopsy revealed metastatic ILC. She was treated with laparoscopic hemicolectomy followed by hormonal therapy and remained asymptomatic at 18-months follow-up.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}